Empagliflozin for heart failure and end-stage kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old.
- You have end-stage kidney disease and have been on stable dialysis for the past 6 months.
- Your heart's pumping strength is below 50%, measured within the last month.
- You do not have severe heart failure symptoms (NYHA class IV).
- You have not been in the hospital for heart failure in the past month.
- You do not have an active urinary or genital infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.